Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task

Archives of General Psychiatry

Volumn 55, Issue 3, 1998, Pages 235-243

  Shihabuddin, Lina ^a   Buchsbaum, Monte S ^a   Hazlett, Erin A ^a   Haznedar, M Mehmet ^a   Harvey, Philip D ^a   Newman, Alan ^a   Schnur, David B ^a   Spiegel Cohen, Jacqueline ^a   Wei, Tsechung ^a   Machac, Josef ^b   Knesaurek, Karin ^b   Vallabhajosula, Shankar ^b   Biren, Melissa A ^a   Ciaravolo, Tina M ^a   Luu Hsia, Christina ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MALE; METABOLIC RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; SCHIZOIDISM; SCHIZOPHRENIA; VERBAL BEHAVIOR; BRAIN METABOLISM; LEARNING TEST; PRIORITY JOURNAL; TASK PERFORMANCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PUTAMEN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; VERBAL LEARNING;

EID: 0032498948     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.3.235     Document Type: Article

References (72)

1. 11C-N-methylspiperone. Psychiatry Res. 1993;49:219-237.
2. 18F-N-methytspiroperidol. Psychiatry Res Neuroimaging. 1996;67:11-16.
3. Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res Neuroimaging. 1996;68:23-30.
4. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. Arch Gen Psychiatry. 1985;42:784-791.
5. Heckers S, Heinsen H, Heinsen Y, Beckmann H. Cortex, white matter, and basal ganglia in schizophrenia: a volumetric postmortem study. Biol Psychiatry. 1991;29:556-566.
6. Kelsoe J, Cadet JL, Pickar D, Weinberger D. Quantitative neuroanatomy in schizophrenia: a controlled magnetic resonance imaging study. Arch Gen Psychiatry. 1988;45:533-541.
7. Jernigan T, Zisook S, Heaton R, Moranville J, Hesselink J, Braff D. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch Gen Psychiatry. 1991;48:881-890.
8. Swayze V, Andreasen N, Alliger R, Yuh W, Ehrhardt J. Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol Psychiatry. 1992;31:221-240.
9. Breier A, Buchanan R, Elkasef A, Munson R, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. Arch Gen Psychiatry. 1992;49:921-926.
10. Buchanan R, Breier A, Kirkpatrick B, Elkashef A, Munson R, Gellad F, Carpenter W. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry. 1993;150:59-65.
11. Hokama H, Shenton ME, Nestor PG, Kikinis R, Levitt JJ, Metcalf D, Wible CG, O'Donnell BF, Jolesz FA, McCarley RW. Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Res Neuroimaging. 1995;61:209-229.
12. Flaum M, Swayze VW, O'Leary DS, Yuh WTC, Ehrhardt JC, Arndt SV, Andreasen NC. Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. Am J Psychiatry. 1995;152:704-714.
13. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M. Increase in caudate nuclei volume of first-episode schizophrenia patients taking antipsychotic drugs. Am J Psychiatry. 1994;151:1430-1436.
14. Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburgers, Alaghband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry. 1996;153:564-566.
15. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancer. 1994;344:1434.
16. Buchsbaum MS, Ingvar DH, Kessler R, Waters RN, Cappelletti J, van Kammen DP, King AC, Johnson JL, Manning RG, Flynn RW, Mann LS, Bunney WE Jr, Sokoloff L. Cerebral glucography with positron tomography. Arch Gen Psychiatry. 1982;39:251-259.
17. Wiesel FA, Wik G, Sjögren I, Blomqvist G, Greitz T, Stone-Elander S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr Scand. 1987;76:628-641.
18. Resnick S, Gur RE, Alavi A, Gur RC, Reivich M. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res. 1988;24:1-11.
19. Buchsbaum MS, Wu J, DeLisi L, Holcomb H, Hazlett E, Cooper-Langston K, Kessler R. Positron emissiom tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol Psychiatry. 1987;22:479-494.
20. Buchsbaum MS, Haier R, Potkin S, Nuechterlein K, Bracha S, Katz M, Lohr J, Wu J, Lottenberg S, Jerabek P, Trenary M, Tafalla R, Reynolds C, Bunney W. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 1992;49:935-942.
21. Wolkin A, Jaeger J, Brodie J, Wolf A, Fowler J, Rotrosen J, Gomez-Mont F, Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry. 1985;142:564-571.
22. Szechtman H, Nahmais C, Garnett S, Firnau G, Brown G, Kaplan R, Cleghorn J. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry. 1988;45:523-532.
23. Cohen R, Semple W, Gross M, Nordahl T, King C, Pickar D, Post R. Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia. Neuropsychopharmacology. 1989;2:241-254.
24. Tamminga C, Thaker G, Buchanan R, Kirkpatrick B, Alphs L, Chase T, Carpenter W. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 1992;49:522-530.
25. Gur RE, Mozley D, Resnick SM, Mozley LH, Shtasel DL, Gallacher F. Arnold SE, Karp JS, Alavi A, Reivich M, Gur RC. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry. 1995;52:657-667.
26. Gur RE, Resnick S, Alavi A, Gur RC, Caroff S, Dann R, Silver F, Saykin A, Chawluk J, Kushner M, Reivich M. Regional brain function in schizophrenia, I: a positron emission tomography study. Arch Gen Psychiatry. 1987;44:119-125.
27. Gur RE, Resnick SM, Gur RC, Alavi A, Caroff S, Kushner M, Reivich M. Regional brain function in schizophrenia, II: repeated evaluation with positron emission tomography. Arch Gen Psychiatry. 1987;44:126-129.
28. Buchsbaum MS, Potkin S, Marshall J, Lottenberg S, Teng C, Heh C, Tafalla R, Reynolds C, Abel L, Plon L, Bunney W. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology. 1992;6:155-163.
29. Saykin AJ, Gur RC, Gur RE. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991 ;48:618-624.
30. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.
31. Yurgelun-Todd DA, Kinney DK. Patterns of neuropsychological deficits that discriminate schizophrenic individuals from siblings and control subjects. J Neuropsychiatry Clin Neurosci. 1993;5:294-300.
32. Heinrichs WR, Awad AG. Neurocognitive subtypes of chronic schizophrenia. Schizophr Res. 1993;9:49-58.
33. Pillon B, Deweer B, Michon A, Malapani C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Neurology. 1994;44:1264-1270.
34. Buytenhuijs EL, Berger JCH, Van Spaendonck KPM, Horstink WIM, Borm GF, Cools AR. Memory and learning strategies in patients with Parkinson's disease. Neuropsychologia. 1994;23:335-342.
35. Beatty WM, Jocic Z, Monson N, Staton RD. Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1993;181:448-453.
36. Buchsbaum MS, Potkin S, Siegel B, Lohr J, Katz M, Gottschalk L, Gulasekaram B, Marshall J, Lottenberg S, Ying Teng C, Abel L, Plon L, Bunney W. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry. 1992;49:966-974.
37. Oldfield RC. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia. 1971;9:97-113.
38. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615-623.
39. Andreasen NC. Thought, language and communication disorders, I: clinical assessment, definition of terms, and evaluation of their reliability. Arch Gen Psychiatry. 1979;36:1315-1321.
40. National Institute of Mental Health. Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: Superintendent of Documents, Government Printing Office; 1976. US Dept of Health, Education, and Welfare publication ADM 76-338.
41. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
42. National Institute of Mental Health. Abnormal Involuntary Movements Scale developed by the Psychopharmacology Branch. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: Superintendent of Documents, Government Printing Office; 1976. US Dept of Health, Education, and Welfare publication ADM 76-338.
43. Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr. 1989;13:20-26.
44. Mountz JM, Wilson MW. Brain structure localization in positron emission tomography: comparison of magnetic resonance imaging and a stereotactic method. Comput Med Imaging Graph. 1991;15:17-22.
45. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
46. Matsui T, Hirano A. An Atlas of the Human Brain for Computerized Tomography. Tokyo, Japan: Igaku-Shoin; 1978.
47. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test. New York, NY: Psychological Corp; 1987.
48. Battig MA. Montague F. Handbook of Semantic Word Norms. Hillsdale, NJ: Lawrence Erlbaum; 1981.
49. Dixon WJ, Brown MB, Engelman L. BMDP Statistical Software. Berkeley: University of California Press; 1985.
50. Poline J-B, Mazoyer BM. Analysis of individual positron emission tomography activation maps by detection of high signal-to-noise-ratio pixel clusters. J Cereb Blood Flow Metab. 1993;13:425-437.
51. 15O-butanol brain activation images. Hum Brain Mapping. 1993;1:3-19.
52. Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dowling S, Pickar D. The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 1988;43:1141-1150.
53. Wik G, Wiesel A, Sjögren I, Blomqvist G, Greitz T, Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizo phrenic patients as determined by emission tomography. Psychopharmacology. 1989;97:309-318.
54. DeLisi LE, Holcomb H, Cohen R, Pickar D, Carpenter W, Morihisa J, King C, Kessler R, Buchsbaum MS. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab. 1985;5:201-206.
55. Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP, Sanfilipo M. Importance of pharmacological control in PET studies: effects of thiothixine and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Hes Neuroimaging. 1991;40:115-124.
56. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry. 1994;151:681-686.
57. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human braIn: PET/FDG studies with and without haloperidol. Am J Psychiatry. 1996;153:41-49.
58. Wolkin A, Sanfilipo M, Duncan E, Angrist B, Wolf A, Cooper T, Brodie J, Laska E, Rotrosen J. Blunted changes in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 1996;153:346-354.
59. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Volkow ND, Wolf AP, Smith G, Wolkin A, Cancro R. Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Psychiatry Res Neuroimaging. 1996;60:91-99.
60. DeLisi LE, Tew W, Xie S, Hoff A, Sakuma M, Kushner M, Lee G, Snedlack K, Smith A, Grimson R. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry. 1995;38:349-360.
61. 2 dopamine receptors in neuroleptic-naive schizophrenia patients. Arch Gen Psychiatry. 1990;47:213-219.
62. Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, Chase GA, Folstein SE. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol. 1992;31:69-75.
63. Benes F, Paskevich P, Davidson J, Domesick V. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res. 1985;329:265-274.
64. Janson AM, Fuxe K, Goldstein M, Deutch AY. Hypertrophy of dopamine neurons in the primate following ventromedial mesencephalic tegmentum lesion. Exp Brain Res. 1991;87:232-238.
65. 2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A. 1994;91:11271-11275.
66. Selemon LD, Goldman-Rakic PS. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci. 1985;55:776-794.
67. Kuwert T, Ganslandt T, Jansen P, Julicher F, Lange H, Herzog H, Scholz A, Feinendegen LE. Influence of size regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr. 1992;16:789-794.
68. 11C]N-methylspiperone Psychiatry Res Neuroimaging. 1995;61:67-83.
69. 123I single photon emission computerized tomography study. Br J Psychiatry. 1994;164:16-26.
70. Reynolds G, Czudek C, Bzowej N, Seeman P. Dopamine receptor asymmetry in schizophrenia. Lancet. 1987;1:979.
71. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 1990;13:254-258.
72. SchrÖder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, Wu J, Potkin SG. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res. 1996;19:41-53.